A comprehensive analysis published in Nature Reviews Disease Primers highlights a critical paradox in Buruli ulcer control across sub-Saharan Africa: while diagnostic and therapeutic innovations continue to advance, they remain largely inaccessible to the populations most affected by this neglected tropical disease. Buruli ulcer, caused by Mycobacterium ulcerans, disproportionately impacts impoverished communities in West and Central Africa, where diagnostic delays often exceed 12 months—a timeline that allows progression from small nodules to extensive, disabling ulceration. The analysis demonstrates that early detection combined with oral antimicrobial therapy can prevent disability in 90% of cases, yet implementation barriers persist. Experts emphasize that strategic investment in decentralized health systems, coupled with integration of community health workers and engagement with traditional healers, represents the most pragmatic pathway to improving outcomes. Success requires balancing cutting-edge diagnostic tools with feasible delivery mechanisms suited to resource-limited settings. Read the full article on GMJ Newsroom.
Was this article helpful?
